# Evaluation of Efficacy and Safety of Dan’e-Fukang Soft Extract in the Treatment of Endometriosis: A Meta-Analysis of 39 Randomized Controlled Trials Enrolling 5442 Patients

Authors: Yantao Li; Te Li; Shilin Song
Journal: Evidence-Based Complementary and Alternative Medicine
 (2017)

---

## Abstract

Objective. To systematically evaluate the efficacy and safety of Dan’e-fukang soft extract in endometriosis treatment.Method. PubMed, CNKI, Wanfang Database, VIP, SinoMed, and Cochrane Library were searched. Randomized controlled trials (RCTs) comparing the efficacy of Dan’e-fukang soft extract and conventional western medicines for endometriosis treatment were included. The data were extracted independently by two people and analyzed using RevMan 5.2.0 software. The relative risk (RR) and mean difference (MD) with 95% confidence intervals were considered as effective outcome indicators.Results. Thirty-nine papers including 5442 patients with endometriosis were included in this study. A meta-analysis revealed that Dan’e-fukang soft extract was more efficient than gestrinone in the treatment of endometriosis (RR = 1.08, 95% CI = 1.03 to 1.15, I2 = 71%, REM, 18 trials) and its efficacy was comparable to that of danazol and mifepristone. Dan’e-fukang soft extract was also as effective as gestrinone and mifepristone in terms of relapse rate and relieving dysmenorrhea. The incidence of adverse reactions was lower than that of conventional western medicines.Conclusions. The results of this study showed that Dan’e-fukang soft extract offers certain advantages in endometriosis treatment, but rigorously designed, strictly implemented RCTs are needed to further validate its efficacy.


---

## Body

## 1. Introduction

Endometriosis (EMs) is an estrogen-dependent gynecological disease in which endometrium-like tissues grows in abnormal sites other than the endometrium, and it can lead to infertility and dysmenorrhea [1]. The global prevalence of endometriosis in women of childbearing age is about 5%–15% [2]. Ectopic lesions at various positions, most commonly in the ovary, and extensive adhesion of pelvic tissues can occur. Laparoscopic surgery is the first choice in the treatment of endometriosis. However, endometriosis treatment without total excision may cause hyperplasia, which leads to recurrence, and the recurrence rate is up to 40% [3]. The drugs currently used in western medicine include danazol, gestrinone, and mifepristone. However, these drugs have serious side effects, and therefore, there is an urgent need to find new, safe, and effective drugs to treat this disease.According to traditional Chinese medicine (TCM), the basic pathogenesis of endometriosis is blood stasis. Therefore, the primary therapy is promoting blood circulation to remove blood stasis. Dan’e-fukang soft extract is the first pure TCM drug that received national drug approval number for the treatment of endometriosis. It consists ofSalvia,Rhizoma Curcumae,Rhizoma Sparganii, bupleurum root, angelica, liquorice,Rhizoma Corydalis,Radix Paeoniae Rubra, andRhizoma Cyperi. Most of the constituents in the prescription disseminate into the hepatic circulation and is involved in coordinating qi and blood, promoting blood circulation to remove blood stasis, and relieving pain. Animal experiments have shown that Dan’e-fukang soft extract helps in modulating immune functions by enhancing cellular immunity and reducing humoral immunity [4]. Currently, Dan’e-fukang soft extract is widely used in clinical practice in China, but it lacks effective evidence-based support. This study will systemically evaluate the clinical efficacy and safety of Dan’e-fukang soft extract in the treatment of endometriosis to provide a reference for clinical management.


## 2. Methods

### 2.1. Inclusion Criteria

Inclusion Criteria. (1) Type of study is as follows: randomized controlled trial (RCT), either blinding or using placebo, and languages limited to Chinese and English. (2) Study candidates are patients who received a diagnosis of endometriosis; endometriosis sites and patients receiving surgeries are not limited. (3) Interventions are as follows: Dan’e-fukang soft extract treatment alone in the test group; medication doses and treatment are not limited; the control group may include patients without treatment or patients receiving placebo or conventional western medicines. The courses of treatment, methods, and dosage are not limited. (4) Outcome measures are as follows: efficacy rate, recurrence rate, remission rate of dysmenorrhea, CA125, and safety.


### 2.2. Search Strategies

PubMed, Cochrane Library, VIP, CNKI, Wanfang Database were searched by computer. The search period ranged from their date of foundation to July 1, 2016. The search terms included Dan’e-fukang soft extract (dan e fu kang jian gao), endometriosis, and random. The references to included literatures were also searched.


### 2.3. Literature Screening

The titles and abstracts of the searched papers were studied by two independent investigators. Trials not obviously meeting the inclusion criteria were excluded. For trials that possibly met the inclusion criteria, the entire papers were further studied to determine if they actually met the inclusion criteria, and they were crosschecked. Disagreements on whether certain trials should be included were resolved through discussions.


### 2.4. Methodological Quality Assessments for Included Studies

Methods recommended by the Cochrane Collaboration were adopted in the methodological quality assessment for RCT, which included six risks of bias assessments: random allocation sequence generation, allocation concealment, blinding, data integrity, selective outcome reporting, and other biases [5]. Entries were considered to have a low risk of bias (low) if they met the criteria and a high risk of bias (high) if they did not meet the criteria. In addition, entries were considered unclear when the paper did not provide enough information for judgment. Methodological quality assessment of clinical trials was performed by two reviewers independently and all disagreements were resolved through discussions.


### 2.5. Data Extraction and Analysis

The two researchers employed unified data extraction forms and independently extracted data, which included general characteristics of the patient, diagnostic criteria, interventions, follow-up, and efficacy evaluation indicators.RevMan 5.2.0 software from the Cochrane Collaboration was used for meta-analysis. Relative risk (RR) was used for count data, mean difference (MD) was used for quantity data, and 95% confidence interval (CI) was used to ascertain the range of the results. The chi-square test was used for assessing the heterogeneity of all clinical trials. For the test of heterogeneity (I2 > 50%, p<0.1), random effects model (REM) was used to analyze the expression effect, whereas a fixed effects model (FEM) was used to merge data.


## 2.1. Inclusion Criteria

Inclusion Criteria. (1) Type of study is as follows: randomized controlled trial (RCT), either blinding or using placebo, and languages limited to Chinese and English. (2) Study candidates are patients who received a diagnosis of endometriosis; endometriosis sites and patients receiving surgeries are not limited. (3) Interventions are as follows: Dan’e-fukang soft extract treatment alone in the test group; medication doses and treatment are not limited; the control group may include patients without treatment or patients receiving placebo or conventional western medicines. The courses of treatment, methods, and dosage are not limited. (4) Outcome measures are as follows: efficacy rate, recurrence rate, remission rate of dysmenorrhea, CA125, and safety.


## 2.2. Search Strategies

PubMed, Cochrane Library, VIP, CNKI, Wanfang Database were searched by computer. The search period ranged from their date of foundation to July 1, 2016. The search terms included Dan’e-fukang soft extract (dan e fu kang jian gao), endometriosis, and random. The references to included literatures were also searched.


## 2.3. Literature Screening

The titles and abstracts of the searched papers were studied by two independent investigators. Trials not obviously meeting the inclusion criteria were excluded. For trials that possibly met the inclusion criteria, the entire papers were further studied to determine if they actually met the inclusion criteria, and they were crosschecked. Disagreements on whether certain trials should be included were resolved through discussions.


## 2.4. Methodological Quality Assessments for Included Studies

Methods recommended by the Cochrane Collaboration were adopted in the methodological quality assessment for RCT, which included six risks of bias assessments: random allocation sequence generation, allocation concealment, blinding, data integrity, selective outcome reporting, and other biases [5]. Entries were considered to have a low risk of bias (low) if they met the criteria and a high risk of bias (high) if they did not meet the criteria. In addition, entries were considered unclear when the paper did not provide enough information for judgment. Methodological quality assessment of clinical trials was performed by two reviewers independently and all disagreements were resolved through discussions.


## 2.5. Data Extraction and Analysis

The two researchers employed unified data extraction forms and independently extracted data, which included general characteristics of the patient, diagnostic criteria, interventions, follow-up, and efficacy evaluation indicators.RevMan 5.2.0 software from the Cochrane Collaboration was used for meta-analysis. Relative risk (RR) was used for count data, mean difference (MD) was used for quantity data, and 95% confidence interval (CI) was used to ascertain the range of the results. The chi-square test was used for assessing the heterogeneity of all clinical trials. For the test of heterogeneity (I2 > 50%, p<0.1), random effects model (REM) was used to analyze the expression effect, whereas a fixed effects model (FEM) was used to merge data.


## 3. Results

### 3.1. Process for Including Literatures

Thirty-nine papers were included in this study [1–39]. The literature searching process is shown in Figure 1.Figure 1
PRISMA 2009 flow diagram.


### 3.2. Characteristics of the Included Studies

5442 endometriosis patients mentioned in the 39 papers were included in this study, with an average sample size of 140 cases. All papers were published Chinese literatures in mainland China. Dan’e-fukang soft extract alone was used in the 39 papers. The control groups were danazol, gestrinone, mifepristone, and marvelon. Laparoscopic postoperative medication was used in 9 papers [8, 13, 17, 25, 26, 31, 39–41]. The features of the included literatures are shown in Table 1.Table 1
Characteristics of enrolling randomized controlled trials.
ID Sample size (I/C) Age (I/C) Surgery Intervention methods Controlled methods Treatment course Following up Outcomes Bi and Wang 2013 23/19 Unreported N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 14 days before menstruation Mifepristone, 12.5 ng each time, 2 times a day 3 months N/A Dysmenorrhea, safety Cai et al. 2004 343/160 35 (16–48) N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 15 days before menstruation Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate Chen WZ 2010 62/58 I: 35.0 ± 3.3; C: 34.0 ± 3.1 Postoperation Dan’e-fukang, 10 g, 1 time a day; Diphereline 3.75 mg intramuscular injection, 28 days once, 3 times totally Diphereline, 3.75 mg intramuscular injection, 28 days once, 6 times totally 6 months 12 months Effective rate, rate of pregnancy, recurrence rate, safety Chen 2009 40/38 I: 30.4 ± 10.0; C: 33.4 ± 8.7 Postoperation Dan’e-fukang, 10 g each time, 3 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months 18 months Rate of pregnancy, recurrence rate, safety X. H. Chen and X. L. Chen 2010 55/55 I: 36.88 ± 5.96; C: 34.13 ± 7.25 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation, keep taken in menstrual period Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, dysmenorrhea, safety Chen 2011 60/60 I: 34 (21–45); C: 31 (19–46) N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, safety Di and Lou 2007 31/29 Unreported N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 10 days before menstruation Mifepristone, 12.5 mg each time, 2 times a day 3 months N/A Effective rate, safety Huang 2012 64/64 I: 29.15 ± 4.65; C: 28.95 ± 4.85 N/A Dan’e-fukang, 10 g each time, 2 times a day Danazol, 200 mg, Mifepristone, 12.5 mg each time, 3 times a day 2 months N/A Effective rate, CA125, safety Huang et al. 2013 38/38 I: 37.4 ± 4.5; C: 34.5 ± 5.1 Postoperation Dan’e-fukang, 15 g each time, 2 times a day; Mifepristone, 10 mg/d, 1 time a day Mifepristone, 10 mg, 1 time a day 3 months N/A Effective rate, recurrence rate, safety Jin et al. 2011 60/60 I: 34 (21–45); C: 31 (19–46) N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 15 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, safety Jin et al. 2013 56/56 I: 32.6 ± 4.7; C: 31.2 ± 4.3 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate, safety Li and Zhu 2010 45/45 18–44 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Mifepristone, 12.5 mg each time 6 months N/A Effective rate 45/45 Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Marvelon, 2.5 mg, 1 time a day Li 2012 47/47 36.6 (22–48) Postoperation Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, recurrence rate, safety Lin and Fu 2006 72/58 I: 33.8 ± 7.3; C: 34.8 ± 6.1 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week 6 months 1 year–3 years Effective rate, CA125, rate of pregnancy, symptom score, safety Shen et al. 2011 28/28 19–42 N/A Dan’e-fukang, 10–15 g each time, 2 times a day; Mifepristone, 6.25 mg, 1 time a day Mifepristone, 10 mg, 1 time a day 3 months 3 months Dysmenorrhea, safety Shen and Wang 2013 96/97 I: 37.0 ± 6.3; C: 36.7 ± 5.8 N/A Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, CA125, safety Tu 2011 343/160 35 (16–48) N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 15 days before menstruation Danazol, 200 mg, 3 times a day 3 months N/A Effective rate, safety >Wang et al. 2013 200/200 Unreported N/A Dan’e-fukang, 10–15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 1 year Dysmenorrhea, recurrence rate, safety Wang 2008 40/40 I: 28.15 (19–45); C: 30 (21–43) N/A Dan’e-fukang, 10 g each time, 2 times a day, Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, safety Wang and Hu 2007 30/30 I: 30 ± 3.5; C: 29 ± 4.4 Postoperation Dan’e-fukang, 15 g each time, 2 times a day No treatment 2 months 12 months Effective rate, rate of pregnancy, recurrence rate, safety Wu et al. 2004 80/42 I: 32 (23–41); C: 32.5 (24–40) N/A Dan’e-fukang, 10–15 g each time, 2 times a day Marvelon, taken on the fifth day of menstruation, 1 tablet a day 3 months N/A Effective rate, improvement of symptoms Xiong et al. 2014 30/30 I: 27.3 ± 1.9; C: 29.1 ± 2.7 Postoperation Dan’e-fukang, 10 g each time, 2 times a day Danazol, 200 g each time, 3 times a day 6 months 6 months Effective rate, recurrence rate, safety Xiong and Wang 2012 65/55 I: 34.3, C: 33.8 N/A Dan’e-fukang, 15 g each time, taken 10 days before menstruation, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 3 months Effective rate, CA125, rate of pregnancy, safety Xu 2011 87/71 I: 36.21 ± 5.25; C: 36.96 ± 5.31 N/A Dan’e-fukang, 15 g each time, taken 10 days before menstruation, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 3 months Effective rate, dysmenorrhea, CA125, rate of pregnancy, safety Xu et al. 2013 72/72 25–49 N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, dysmenorrhea, safety Yang 2015 91/92 I: 37.01 ± 6.3; C: 36.7 ± 5.8 N/A Dan’e-fukang, 10 g each time Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, CA125, rate of pregnancy, safety Yang et al. 2010 37/34 Unreported Postoperation Dan’e-fukang, 10 g each time, 2 times a day Mifepristone, 10 mg each time, 1 time a day 6 months N/A Effective rate, rate of pregnancy, recurrence rate, safety Yao 2005 60/60 I: 28.5 (23–40); C: 30 (21–43) N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time 6 months N/A Effective rate, safety Yao et al. 2013 60/60 36 (18–50) N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 15 days before menstruation Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate Yin et al. 2014 60/60 I: 34.9 ± 7.1; C: 35.9 ± 5.9 N/A Dan’e-fukang, 10 g each time, 2 times a day Intrauterine placed Mirena 9 months N/A Effective rate Zhang et al. 2010 60/30 33.4 (20–53) N/A Dan’e-fukang, 10–15 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week; 3 months N/A Dysmenorrhea, safety 60/20 Dan’e-fukang, 10–15 g each time, 2 times a day, taken 10 days before menstruation Placebo Zhang and Li 2008 53/50 36 (18–50) N/A Dan’e-fukang, 10 g each time, 2 times a day Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate, safety Zhang and Li 2007 40/35 I: 33.0 ± 2.7; C: 34.0 ± 5.4 Postoperation Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, rate of pregnancy, safety Zhang and Ren 2008 112/43 34.6 (19–48) N/A Dan’e-fukang, 15 g each time, 2 times a day, Danazol, 200 mg each time, 2 times a day 3 months 3 months Effective rate Zhao 2013 75/75 I: 35.9 ± 5.68; C: 36.7 ± 6.8 Postoperation Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 7 months N/A Effective rate, recurrence rate, safety Zhao et al. 2011 18/20 21–42 Postoperation Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week 6 months 1 year Effective rate, hormone level X. H. Zheng and J. B. Zheng 2015 105/105 I: 36.25 ± 4.35; C: 36.05 ± 4.01 N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg/d, the first taken on the first day of menstruation, the second taken on the fourth day of menstruation 3 months N/A Effective rate, dysmenorrhea, CA125, rate of pregnancy, safety Zhu 2010 50/41 I: 36.19 ± 4.66; C: 37.34 ± 4.98 N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 3 months Dysmenorrhea, safety Zhu 2013 32/32 35.8 ± 2.3 N/A Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, CA125, safety Zhu and Lei 2010 50/50 36.19 ± 4.84 Postoperation Dan’e-fukang, 10 g each time, 2 times a day, taken 1 week after operation Gestrinone, 2.5 mg each time, 2 times a week, taken 1 week after operation 6 months 3 years Effective rate, dysmenorrhea, recurrence rate, improvement of symptoms


### 3.3. The Methodological Quality of Included Studies

The studies were biased with high risks and the quality was low in all included papers. Wherein six papers used a random number table to randomize the groups [9, 28, 34, 39, 42, 43], other papers merely mentioned the word “randomized” in the text. Random allocation concealment and blinding were not mentioned in all the papers. Placebo was used in one paper, but no detailed placebo information was reported [34]. No exit and lost cases were reported in the six papers that were rated as low risk of bias [8, 16, 26, 28, 34, 43]. Exit and lost cases were reported in two papers, but intention analysis was not done; therefore, it was rated as high risk of bias [6, 38]. No details were reported in other papers, and they were rated as “unclear.” Since program registrations were conducted in none of the included studies, the selection bias was “unclear” for most of the studies. However, there were discrepancies in the methodology and results in four papers, and they were rated as high risk of bias [6, 11, 16, 44]. The principle for estimating the sample amount was not reported in any of the included studies. The methodological quality of the included studies is shown in Figures 2 and 3.Figure 2
Risk of bias graph.Figure 3
Risk of bias summary.


### 3.4. Efficiency of Dan’e-Fukang Soft Extract in the Treatment of Endometriosis

#### 3.4.1. Efficiency

The efficiency of Dan’e-fukang soft extract and gestrinone in the treatment of endometriosis was compared in 18 papers, and there was no significant difference in the efficacy (P<0.05) in 10 papers. However, meta-analysis showed that Dan’e-fukang soft extract was superior to gestrinone (RR = 1.08, 95% CI from 1.03 to 1.15, I2 = 71%, REM). The efficiency of Dan’e-fukang soft extract and danazol was compared in 8 papers, and the meta-analysis showed no significant difference in efficacy (RR = 0.99, 95% CI from 0.96 to 1.01, I2 = 0%, REM). The efficiency of Dan’e-fukang soft extract and mifepristone was compared in 3 studies, and meta-analysis showed no significant difference in efficacy (RR = 1.02, 95% CI from 0.95 to 1.10, I2 = 0%, REM). The detailed results are shown in Figure 4.Figure 4
Forest plot of effective rate.


#### 3.4.2. Recurrence Rate

Meta-analysis of five papers showed that the recurrence rate of Dan’e-fukang soft extract was lower than gestrinone in the treatment of endometriosis (RR = 0.46, 95% CI from 0.23 to 0.90,I2 = 71%, REM). However, meta-analysis of two papers showed that there was no significant difference between Dan’e-fukang soft extract and mifepristone in reducing the recurrence rate of endometriosis (RR = 0.33, 95% CI from 0.07 to 1.61, I2 = 0%, REM). The detailed results are shown in Figure 5.Figure 5
Forest plot of recurrence rate.


#### 3.4.3. Degree of Ease of Dysmenorrhea

The meta-analysis of five papers showed that there was no significant difference between Dan’e-fukang soft extract and gestrinone in the treatment of endometriosis and remission rate of dysmenorrhea (RR = 1.01, 95% CI from 0.96 to 1.06,I2 = 42%, FEM). The meta-analysis of two papers showed no difference between Dan’e-fukang soft extract and mifepristone in terms of relief of dysmenorrhea (RR = 0.97, 95% CI from 0.82 to 1.16, I2 = 0%, FEM). The detailed results are shown in Figure 6.Figure 6
Forest plot of dysmenorrhea relieve rate.


#### 3.4.4. CA125

Meta-analysis of seven papers showed that Dan’e-fukang soft extract was superior to gestrinone in the treatment of endometriosis by regulating CA125 (MD = −5.38, 95% CI from −9.05 to −1.70,I2 = 89%, REM). The detailed results are shown in Figure 7.Figure 7
Forest plot of CA125.


#### 3.4.5. Adverse Reactions

No significantly adverse reactions occurred in the Dan’e-fukang soft extract-treated groups in 18 papers, while adverse reactions, such as weight gain, acne, menstrual disorders, abnormal vaginal bleeding, and abnormal liver function, were reported in the western medicine-treated control groups. However, no further meta-analysis could be done because the various symptoms were not standardized. The overall incidence of adverse reactions was reported in six studies and the meta-analysis showed that the adverse reactions in the Dan’e-fukang soft extract group were less than that of the western medicine groups (RR = 0.14, 95% CI = 0.06 to 0.32,I2 = 50%, REM). The detailed results are shown in Figure 8.Figure 8
Forest plot of adverse reactions.


## 3.1. Process for Including Literatures

Thirty-nine papers were included in this study [1–39]. The literature searching process is shown in Figure 1.Figure 1
PRISMA 2009 flow diagram.


## 3.2. Characteristics of the Included Studies

5442 endometriosis patients mentioned in the 39 papers were included in this study, with an average sample size of 140 cases. All papers were published Chinese literatures in mainland China. Dan’e-fukang soft extract alone was used in the 39 papers. The control groups were danazol, gestrinone, mifepristone, and marvelon. Laparoscopic postoperative medication was used in 9 papers [8, 13, 17, 25, 26, 31, 39–41]. The features of the included literatures are shown in Table 1.Table 1
Characteristics of enrolling randomized controlled trials.
ID Sample size (I/C) Age (I/C) Surgery Intervention methods Controlled methods Treatment course Following up Outcomes Bi and Wang 2013 23/19 Unreported N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 14 days before menstruation Mifepristone, 12.5 ng each time, 2 times a day 3 months N/A Dysmenorrhea, safety Cai et al. 2004 343/160 35 (16–48) N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 15 days before menstruation Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate Chen WZ 2010 62/58 I: 35.0 ± 3.3; C: 34.0 ± 3.1 Postoperation Dan’e-fukang, 10 g, 1 time a day; Diphereline 3.75 mg intramuscular injection, 28 days once, 3 times totally Diphereline, 3.75 mg intramuscular injection, 28 days once, 6 times totally 6 months 12 months Effective rate, rate of pregnancy, recurrence rate, safety Chen 2009 40/38 I: 30.4 ± 10.0; C: 33.4 ± 8.7 Postoperation Dan’e-fukang, 10 g each time, 3 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months 18 months Rate of pregnancy, recurrence rate, safety X. H. Chen and X. L. Chen 2010 55/55 I: 36.88 ± 5.96; C: 34.13 ± 7.25 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation, keep taken in menstrual period Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, dysmenorrhea, safety Chen 2011 60/60 I: 34 (21–45); C: 31 (19–46) N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, safety Di and Lou 2007 31/29 Unreported N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 10 days before menstruation Mifepristone, 12.5 mg each time, 2 times a day 3 months N/A Effective rate, safety Huang 2012 64/64 I: 29.15 ± 4.65; C: 28.95 ± 4.85 N/A Dan’e-fukang, 10 g each time, 2 times a day Danazol, 200 mg, Mifepristone, 12.5 mg each time, 3 times a day 2 months N/A Effective rate, CA125, safety Huang et al. 2013 38/38 I: 37.4 ± 4.5; C: 34.5 ± 5.1 Postoperation Dan’e-fukang, 15 g each time, 2 times a day; Mifepristone, 10 mg/d, 1 time a day Mifepristone, 10 mg, 1 time a day 3 months N/A Effective rate, recurrence rate, safety Jin et al. 2011 60/60 I: 34 (21–45); C: 31 (19–46) N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 15 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, safety Jin et al. 2013 56/56 I: 32.6 ± 4.7; C: 31.2 ± 4.3 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate, safety Li and Zhu 2010 45/45 18–44 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Mifepristone, 12.5 mg each time 6 months N/A Effective rate 45/45 Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Marvelon, 2.5 mg, 1 time a day Li 2012 47/47 36.6 (22–48) Postoperation Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, recurrence rate, safety Lin and Fu 2006 72/58 I: 33.8 ± 7.3; C: 34.8 ± 6.1 N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week 6 months 1 year–3 years Effective rate, CA125, rate of pregnancy, symptom score, safety Shen et al. 2011 28/28 19–42 N/A Dan’e-fukang, 10–15 g each time, 2 times a day; Mifepristone, 6.25 mg, 1 time a day Mifepristone, 10 mg, 1 time a day 3 months 3 months Dysmenorrhea, safety Shen and Wang 2013 96/97 I: 37.0 ± 6.3; C: 36.7 ± 5.8 N/A Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, CA125, safety Tu 2011 343/160 35 (16–48) N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 15 days before menstruation Danazol, 200 mg, 3 times a day 3 months N/A Effective rate, safety >Wang et al. 2013 200/200 Unreported N/A Dan’e-fukang, 10–15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 1 year Dysmenorrhea, recurrence rate, safety Wang 2008 40/40 I: 28.15 (19–45); C: 30 (21–43) N/A Dan’e-fukang, 10 g each time, 2 times a day, Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, safety Wang and Hu 2007 30/30 I: 30 ± 3.5; C: 29 ± 4.4 Postoperation Dan’e-fukang, 15 g each time, 2 times a day No treatment 2 months 12 months Effective rate, rate of pregnancy, recurrence rate, safety Wu et al. 2004 80/42 I: 32 (23–41); C: 32.5 (24–40) N/A Dan’e-fukang, 10–15 g each time, 2 times a day Marvelon, taken on the fifth day of menstruation, 1 tablet a day 3 months N/A Effective rate, improvement of symptoms Xiong et al. 2014 30/30 I: 27.3 ± 1.9; C: 29.1 ± 2.7 Postoperation Dan’e-fukang, 10 g each time, 2 times a day Danazol, 200 g each time, 3 times a day 6 months 6 months Effective rate, recurrence rate, safety Xiong and Wang 2012 65/55 I: 34.3, C: 33.8 N/A Dan’e-fukang, 15 g each time, taken 10 days before menstruation, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 3 months Effective rate, CA125, rate of pregnancy, safety Xu 2011 87/71 I: 36.21 ± 5.25; C: 36.96 ± 5.31 N/A Dan’e-fukang, 15 g each time, taken 10 days before menstruation, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 3 months Effective rate, dysmenorrhea, CA125, rate of pregnancy, safety Xu et al. 2013 72/72 25–49 N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, dysmenorrhea, safety Yang 2015 91/92 I: 37.01 ± 6.3; C: 36.7 ± 5.8 N/A Dan’e-fukang, 10 g each time Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, CA125, rate of pregnancy, safety Yang et al. 2010 37/34 Unreported Postoperation Dan’e-fukang, 10 g each time, 2 times a day Mifepristone, 10 mg each time, 1 time a day 6 months N/A Effective rate, rate of pregnancy, recurrence rate, safety Yao 2005 60/60 I: 28.5 (23–40); C: 30 (21–43) N/A Dan’e-fukang, 10 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time 6 months N/A Effective rate, safety Yao et al. 2013 60/60 36 (18–50) N/A Dan’e-fukang, 15 g each time, 2 times a day, taken 15 days before menstruation Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate Yin et al. 2014 60/60 I: 34.9 ± 7.1; C: 35.9 ± 5.9 N/A Dan’e-fukang, 10 g each time, 2 times a day Intrauterine placed Mirena 9 months N/A Effective rate Zhang et al. 2010 60/30 33.4 (20–53) N/A Dan’e-fukang, 10–15 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week; 3 months N/A Dysmenorrhea, safety 60/20 Dan’e-fukang, 10–15 g each time, 2 times a day, taken 10 days before menstruation Placebo Zhang and Li 2008 53/50 36 (18–50) N/A Dan’e-fukang, 10 g each time, 2 times a day Danazol, 200 mg each time, 3 times a day 3 months N/A Effective rate, safety Zhang and Li 2007 40/35 I: 33.0 ± 2.7; C: 34.0 ± 5.4 Postoperation Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months N/A Effective rate, rate of pregnancy, safety Zhang and Ren 2008 112/43 34.6 (19–48) N/A Dan’e-fukang, 15 g each time, 2 times a day, Danazol, 200 mg each time, 2 times a day 3 months 3 months Effective rate Zhao 2013 75/75 I: 35.9 ± 5.68; C: 36.7 ± 6.8 Postoperation Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 7 months N/A Effective rate, recurrence rate, safety Zhao et al. 2011 18/20 21–42 Postoperation Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation Gestrinone, 2.5 mg each time, 2 times a week 6 months 1 year Effective rate, hormone level X. H. Zheng and J. B. Zheng 2015 105/105 I: 36.25 ± 4.35; C: 36.05 ± 4.01 N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg/d, the first taken on the first day of menstruation, the second taken on the fourth day of menstruation 3 months N/A Effective rate, dysmenorrhea, CA125, rate of pregnancy, safety Zhu 2010 50/41 I: 36.19 ± 4.66; C: 37.34 ± 4.98 N/A Dan’e-fukang, 15 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 3 months 3 months Dysmenorrhea, safety Zhu 2013 32/32 35.8 ± 2.3 N/A Dan’e-fukang, 10 g each time, 2 times a day Gestrinone, 2.5 mg each time, 2 times a week 6 months N/A Effective rate, CA125, safety Zhu and Lei 2010 50/50 36.19 ± 4.84 Postoperation Dan’e-fukang, 10 g each time, 2 times a day, taken 1 week after operation Gestrinone, 2.5 mg each time, 2 times a week, taken 1 week after operation 6 months 3 years Effective rate, dysmenorrhea, recurrence rate, improvement of symptoms


## 3.3. The Methodological Quality of Included Studies

The studies were biased with high risks and the quality was low in all included papers. Wherein six papers used a random number table to randomize the groups [9, 28, 34, 39, 42, 43], other papers merely mentioned the word “randomized” in the text. Random allocation concealment and blinding were not mentioned in all the papers. Placebo was used in one paper, but no detailed placebo information was reported [34]. No exit and lost cases were reported in the six papers that were rated as low risk of bias [8, 16, 26, 28, 34, 43]. Exit and lost cases were reported in two papers, but intention analysis was not done; therefore, it was rated as high risk of bias [6, 38]. No details were reported in other papers, and they were rated as “unclear.” Since program registrations were conducted in none of the included studies, the selection bias was “unclear” for most of the studies. However, there were discrepancies in the methodology and results in four papers, and they were rated as high risk of bias [6, 11, 16, 44]. The principle for estimating the sample amount was not reported in any of the included studies. The methodological quality of the included studies is shown in Figures 2 and 3.Figure 2
Risk of bias graph.Figure 3
Risk of bias summary.


## 3.4. Efficiency of Dan’e-Fukang Soft Extract in the Treatment of Endometriosis

### 3.4.1. Efficiency

The efficiency of Dan’e-fukang soft extract and gestrinone in the treatment of endometriosis was compared in 18 papers, and there was no significant difference in the efficacy (P<0.05) in 10 papers. However, meta-analysis showed that Dan’e-fukang soft extract was superior to gestrinone (RR = 1.08, 95% CI from 1.03 to 1.15, I2 = 71%, REM). The efficiency of Dan’e-fukang soft extract and danazol was compared in 8 papers, and the meta-analysis showed no significant difference in efficacy (RR = 0.99, 95% CI from 0.96 to 1.01, I2 = 0%, REM). The efficiency of Dan’e-fukang soft extract and mifepristone was compared in 3 studies, and meta-analysis showed no significant difference in efficacy (RR = 1.02, 95% CI from 0.95 to 1.10, I2 = 0%, REM). The detailed results are shown in Figure 4.Figure 4
Forest plot of effective rate.


### 3.4.2. Recurrence Rate

Meta-analysis of five papers showed that the recurrence rate of Dan’e-fukang soft extract was lower than gestrinone in the treatment of endometriosis (RR = 0.46, 95% CI from 0.23 to 0.90,I2 = 71%, REM). However, meta-analysis of two papers showed that there was no significant difference between Dan’e-fukang soft extract and mifepristone in reducing the recurrence rate of endometriosis (RR = 0.33, 95% CI from 0.07 to 1.61, I2 = 0%, REM). The detailed results are shown in Figure 5.Figure 5
Forest plot of recurrence rate.


### 3.4.3. Degree of Ease of Dysmenorrhea

The meta-analysis of five papers showed that there was no significant difference between Dan’e-fukang soft extract and gestrinone in the treatment of endometriosis and remission rate of dysmenorrhea (RR = 1.01, 95% CI from 0.96 to 1.06,I2 = 42%, FEM). The meta-analysis of two papers showed no difference between Dan’e-fukang soft extract and mifepristone in terms of relief of dysmenorrhea (RR = 0.97, 95% CI from 0.82 to 1.16, I2 = 0%, FEM). The detailed results are shown in Figure 6.Figure 6
Forest plot of dysmenorrhea relieve rate.


### 3.4.4. CA125

Meta-analysis of seven papers showed that Dan’e-fukang soft extract was superior to gestrinone in the treatment of endometriosis by regulating CA125 (MD = −5.38, 95% CI from −9.05 to −1.70,I2 = 89%, REM). The detailed results are shown in Figure 7.Figure 7
Forest plot of CA125.


### 3.4.5. Adverse Reactions

No significantly adverse reactions occurred in the Dan’e-fukang soft extract-treated groups in 18 papers, while adverse reactions, such as weight gain, acne, menstrual disorders, abnormal vaginal bleeding, and abnormal liver function, were reported in the western medicine-treated control groups. However, no further meta-analysis could be done because the various symptoms were not standardized. The overall incidence of adverse reactions was reported in six studies and the meta-analysis showed that the adverse reactions in the Dan’e-fukang soft extract group were less than that of the western medicine groups (RR = 0.14, 95% CI = 0.06 to 0.32,I2 = 50%, REM). The detailed results are shown in Figure 8.Figure 8
Forest plot of adverse reactions.


## 3.4.1. Efficiency

The efficiency of Dan’e-fukang soft extract and gestrinone in the treatment of endometriosis was compared in 18 papers, and there was no significant difference in the efficacy (P<0.05) in 10 papers. However, meta-analysis showed that Dan’e-fukang soft extract was superior to gestrinone (RR = 1.08, 95% CI from 1.03 to 1.15, I2 = 71%, REM). The efficiency of Dan’e-fukang soft extract and danazol was compared in 8 papers, and the meta-analysis showed no significant difference in efficacy (RR = 0.99, 95% CI from 0.96 to 1.01, I2 = 0%, REM). The efficiency of Dan’e-fukang soft extract and mifepristone was compared in 3 studies, and meta-analysis showed no significant difference in efficacy (RR = 1.02, 95% CI from 0.95 to 1.10, I2 = 0%, REM). The detailed results are shown in Figure 4.Figure 4
Forest plot of effective rate.


## 3.4.2. Recurrence Rate

Meta-analysis of five papers showed that the recurrence rate of Dan’e-fukang soft extract was lower than gestrinone in the treatment of endometriosis (RR = 0.46, 95% CI from 0.23 to 0.90,I2 = 71%, REM). However, meta-analysis of two papers showed that there was no significant difference between Dan’e-fukang soft extract and mifepristone in reducing the recurrence rate of endometriosis (RR = 0.33, 95% CI from 0.07 to 1.61, I2 = 0%, REM). The detailed results are shown in Figure 5.Figure 5
Forest plot of recurrence rate.


## 3.4.3. Degree of Ease of Dysmenorrhea

The meta-analysis of five papers showed that there was no significant difference between Dan’e-fukang soft extract and gestrinone in the treatment of endometriosis and remission rate of dysmenorrhea (RR = 1.01, 95% CI from 0.96 to 1.06,I2 = 42%, FEM). The meta-analysis of two papers showed no difference between Dan’e-fukang soft extract and mifepristone in terms of relief of dysmenorrhea (RR = 0.97, 95% CI from 0.82 to 1.16, I2 = 0%, FEM). The detailed results are shown in Figure 6.Figure 6
Forest plot of dysmenorrhea relieve rate.


## 3.4.4. CA125

Meta-analysis of seven papers showed that Dan’e-fukang soft extract was superior to gestrinone in the treatment of endometriosis by regulating CA125 (MD = −5.38, 95% CI from −9.05 to −1.70,I2 = 89%, REM). The detailed results are shown in Figure 7.Figure 7
Forest plot of CA125.


## 3.4.5. Adverse Reactions

No significantly adverse reactions occurred in the Dan’e-fukang soft extract-treated groups in 18 papers, while adverse reactions, such as weight gain, acne, menstrual disorders, abnormal vaginal bleeding, and abnormal liver function, were reported in the western medicine-treated control groups. However, no further meta-analysis could be done because the various symptoms were not standardized. The overall incidence of adverse reactions was reported in six studies and the meta-analysis showed that the adverse reactions in the Dan’e-fukang soft extract group were less than that of the western medicine groups (RR = 0.14, 95% CI = 0.06 to 0.32,I2 = 50%, REM). The detailed results are shown in Figure 8.Figure 8
Forest plot of adverse reactions.


## 4. Discussion

Endometriosis is a common hormone-dependent gynecological disease, mainly treated with surgeries and western medicines. The recurrence rate is high because invisible lesions cannot be effectively removed with surgeries. The commonly used drugs include gestrinone, danazol, and mifepristone. Not only are they expensive, but also have serious drug side effects, commonly causing damage to the liver and kidney. Moreover, they induce masculinity, which greatly affects the quality of life in patients.Dan’e-fukang soft extract is composed of two key herbs: Danshen (Salvia miltiorrhiza) and Ezhu (Curcuma zedoaria).Salvia miltiorrhiza, well known for its characters in treating of heart and vascular diseases, has also been explored extensively for treating other diseases [45, 46], and it is documented in the United States Pharmacopeial Convention [47]. Classified by structural characteristics and chemical properties, the compounds isolated from Danshen can be categorized as water-soluble and lipid-soluble constituents [48]. Water-soluble constituents mainly exhibit cardiovascular protective activities [49–51]. The lipid-soluble constituents show properties of anticancer and anti-inflammation [52–55]. Family Zingiberaceae consisting of about 1400 species and 47 genera has been used in medicine for centuries [56]. Ezhu (Curcuma zedoaria) also known as white turmeric, kachur, and zedoary is a continuing herb belonging to family Zingiberaceae which is cultivated all over Asia. It is used traditionally to treat inflammation, pain, and a variety of skin ailments including wounds, as well as menstrual irregularities and ulcers [57].Curcuma zedoaria is being used as anti-inflammatory, carminative, antitumor, gastrointestinal stimulant, antiulcer, stomachic, antiallergic, diuretic, hepatoprotective, antinociceptive, demulcent, expectorant, rubefacient, and antimicrobial agents [57–61]. Endometriosis, based on an estrogen-inflammation dependent and blood supply disorder [62], Danshen (Salvia miltiorrhiza), and Ezhu (Curcuma zedoaria), theoretically, are better choices for the treatment on the disease.The results of this study showed that Dan’e-fukang soft extract was superior to gestrinone in treatment of endometriosis, and its efficiency was comparable to that of danazol and mifepristone. It is important to note that adverse reactions in Dan’e-fukang soft extract group were significantly lower than the western medicine group, indicating that Dan’e-fukang soft extract can improve endometriosis to a certain degree, and it is worth further exploration. However, the quality of the literature included in this study was generally low; therefore, a firm conclusion could not be drawn.The generally low methodological quality of the included literature is a limitation of this study. The reasons for the low quality are as follows: (1) some subjective bias may exist as no placebo-controlled and blinded trials were implemented in the studies; (2) selective reporting bias cannot be ruled out as no proposals were registered and published in the studies; and (3) no detailed randomization methods were reported in most studies and the term “randomized” was merely mentioned. Therefore, only a part of the studies is true “randomized controlled trials"; (4) the efficacy evaluation of the included studies was mainly based on compound outcomes; for example, the degree of improvement based on multiple symptoms is divided into four levels: cured, obvious effective, effective, and ineffective. Since judging criteria in the studies are inconsistent, misclassification bias might exist. In future, rigorously designed, large-scale, multicenter RCTs are recommended to further validate the efficacy of Dan’e-fukang soft extract and to draw more reliable conclusions.


## 5. Conclusion

The results of this study show that Dan’e-fukang soft extract offers certain advantages in endometriosis treatment. However, because the methodological quality of the included studies was low, rigorously designed and strictly implemented RCTs are needed to further validate its efficacy.



---

*Source: 9767391-2017-02-27.xml*